1. Home
  2. PDS vs GERN Comparison

PDS vs GERN Comparison

Compare PDS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precision Drilling Corporation

PDS

Precision Drilling Corporation

HOLD

Current Price

$96.30

Market Cap

918.1M

Sector

N/A

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.55

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDS
GERN
Founded
1951
1990
Country
Canada
United States
Employees
N/A
229
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
918.1M
1.1B
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
PDS
GERN
Price
$96.30
$1.55
Analyst Decision
Buy
Hold
Analyst Count
2
3
Target Price
$114.50
$2.17
AVG Volume (30 Days)
126.3K
17.5M
Earning Date
04-22-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.09
$26.91
Revenue Next Year
$2.10
$43.75
P/E Ratio
$884.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.20
$1.04
52 Week High
$97.13
$2.01

Technical Indicators

Market Signals
Indicator
PDS
GERN
Relative Strength Index (RSI) 72.77 47.03
Support Level $54.77 $1.23
Resistance Level N/A $1.68
Average True Range (ATR) 2.91 0.11
MACD 0.25 -0.01
Stochastic Oscillator 92.55 41.43

Price Performance

Historical Comparison
PDS
GERN

About PDS Precision Drilling Corporation

Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: